INVESTMENT OPPORTUNITIES

ITALY ON THE MOVE 2021

A DIGITAL SIDE EVENT AND ONE ON ONE MEETING SESSIONS DURING

The 39th Annual J.P.Morgan HEALTHCARE CONFERENCE

Wednesday, January 13, 2021| 8:00 am PT

ONE ON ONE MEETINGS:
January 11-22, 2021 | 8:00 am to 10:00 am PT



INDEX

COMPANIES

Pag.

ACHILLES VACCINES

AREA OF ACTIVITY
Vaccines

FOUNDED
2017

HEADQUARTERS
Via Fiorentina 1,
53100, Siena
Italy

www.achillesvaccines.com

MEETING'S GOAL

Partnership and Fundraising

CLINICAL INDICATION / TARGET MARKET

Platform based vaccines and immuno-therapeutics to combat emerging and pandemic diseases.

ASSET DESCRIPTION

Modified Outer Membrane Vesicles (mOMV) are membrane blebs shed by bacteria that can be genetically modified for product optimization. mOMV are a safe, highly immunogenic, powerful platform to deliver protective antigens from pathogens and immuno-therapeutic molecules. mOMV allow versatile and rapid incorporation of new molecules, followed by fast production, low costs, scalability and sustainability of supply. These are critical advantages in the development of global measures against known and unknown disease threats. Discovery and development of mOMV based products will be boosted by AchilleS Vaccines Biotech Lab 4.0, a new model for early-stage development of new biopharmaceutical products and pre-clinical R&D.

ASSET DEVELOPMENT STAGE

Discovery and Preclinical

ALTHEIA SCIENCE

AREA OF ACTIVITY
Biotech

FOUNDED
2017

HEADQUARTERS
Via Enrico Besana, 7
Milan (MI)
Italy

www.altheiascience.com

MEETING'S GOAL

Fundraising

CLINICAL INDICATION / TARGET MARKET

Altheia Science, exploiting the scientific and management expertise of the company, intends to promote the product development at international level, not only in Italy but also in Europe and in the USA. Product development includes the execution of IND-enabling studies focused on the demonstration of a favorable benefit/risk ratio, on safety and on the design of appropriate clinical development plans. Finance partners in the USA would favor the enablement of this process.

ASSET DESCRIPTION

Altheia Science develops pioneering therapeutic tools for autoimmune diseases and cancer. The modulation of PD-L1 expression at the molecular and protein level is key to devising advanced treatments in autoimmune diseases, and this can be achieved by first-in-class molecules controlling the PD-L1 pathway and/or by lentiviral vector-based engineering of patients' hematopoietic stem and progenitor cells. The primary goal of Altheia Science is, via a one-time stem cell gene therapy aimed at reverting the root cause of the disease, to develop transformative therapies for type I diabetes and multiple sclerosis, characterized by autoimmune destruction of insulin-producing β cells and myelin, respectively, leading to severe clinical sequelae, life-threatening conditions and death. No definitive cure is presently available. Altheia Science's approach aims at inducing a long-lasting control of the auto-immune reaction, eventually promoting tolerance and a correct immune balance, thus potentially offering a definitive therapy. Altheia Science in-licensed from Children's Medical Center Corporation - Boston Children's Hospital the intellectual property rights to develop curative and definitive medicines for autoimmune diseases. Altheia Science's core expertise includes competences and track record in developing up to market advanced therapy medicinal products in autoimmunity, stem cell transplantation and cell & gene therapy.

ASSET DEVELOPMENT STAGE

Preclinical development

AXESS4YOU

AREA OF ACTIVITY
IT
Application for Health

FOUNDED
2020

HEADQUARTERS
Milan, Italy

www.axess4you.com

MEETING'S GOAL

Partnership and Fundraising

CLINICAL INDICATION / TARGET MARKET

SMEs launching new technologies in need of support in access and pricing.

ASSET DESCRIPTION

Axess4You is an AI Value-Based Contracting Platform able to accelerate negotiations, time-to-market and enhance revenues of new therapies.

ASSET DEVELOPMENT STAGE

Experimental Proof of Concept, Market Validated

BIOMVIS

AREA OF ACTIVITY
Vaccines

FOUNDED
2017

HEADQUARTERS
Via Fiorentina 1,
53100 Siena, Italy

www.biomvis.com

MEETING'S GOAL

Infectious diseases Vaccines and cancer immunotherapy.

CLINICAL INDICATION / TARGET MARKET

1) Out-licensing of the OMV-based vaccine platform for specific indications,
2) Fundraising for moving two infectious disease vaccines and personalized cancer vaccines to Phase I.

ASSET DESCRIPTION

By using Synthetic Biology on non-pathogenic E. coli, BiOMViS has developed a unique vaccine platform based on Proteome-minimized bacterial Outer Membrane Vesicles (OMVs). Thanks to (i) the potent intrinsic adjuvanticity of OMVs, (ii) the availability of proprietary technologies for OMVs engineering with multiple antigens, and (iii) the ease with which OMVs can be purified from bacterial culture supernatants, BiOMViS is exploiting its unique OMV platform for the production of innovating vaccines against infectious diseases and cancer.

ASSET DEVELOPMENT STAGE

Preclinical phase ready to move to development.

COMPLEXDATA

AREA OF ACTIVITY
Bioinformatics,
Big data analytics

FOUNDED
2018

HEADQUARTERS
Corso Di Porta Romana 132 20122,
Milano, Italy

www.complexdata.it

MEETING'S GOAL

Fundraising

CLINICAL INDICATION / TARGET MARKET

Patients with tumors / hospitals

ASSET DESCRIPTION

ARIADNE is a tool that can help doctors understand the biological features of a tumor and thus decide a personalized therapeutic strategy. ARIADNE uses the fingerprint of a cell represented by the transcriptome which considers the interaction of the environment on the genome. ARIADNE starts from a breast bioptic sample and compute the risk of aggressiveness (RA), delivering an easily readable report displaying the RA using a color bar going from green (negative test, low aggressiveness) to red (positive test, high aggressiveness).

ASSET DEVELOPMENT STAGE

Type 2 Medical Device

DEEPMAMMO APTUS

AREA OF ACTIVITY
Bioinformatics,
Big data analytics

FOUNDED
2018

HEADQUARTERS
Via Mecherini, PISA, Italy

aptus.ai/deepmammo

MEETING'S GOAL

Fundraising
Corporate and B2B partnerships.

CLINICAL INDICATION / TARGET MARKET

As a MedTech startup we are focusing on Artificial Intelligence applied to radiology workflows and digital imaging. We support radiologist in early detection of Breast Cancer, applying Image Recognition and Deep Neural Networks to detect cancer in mammograms.

ASSET DESCRIPTION

We propose DeepMammo, the Artificial Intelligence empowering radiologists in early detection of breast cancer.

ASSET DEVELOPMENT STAGE

MVP in progress, next milestone is preclinical validation.

DIATHEVA

AREA OF ACTIVITY
Biotech

FOUNDED
2002

HEADQUARTERS
Cartoceto (PU), Italy

www.diatheva.com

MEETING'S GOAL

Out-licensing, co-development or other partnering opportunities.

CLINICAL INDICATION / TARGET MARKET

Human recombinant antibodies for oncology and infectious diseases.
Anti-CD99: Acute leukemia (AML and T-ALL), Ewing'sarcoma
Anti-CEACAM1: Immunocheckpoint inhibitor
Anti- Beta 1,3 glucans: Fungal infections

ASSET DESCRIPTION

Anti-CD99: DIATHEVA lead candidate in oncology is a new fully human recombinant monoclonal antibody in late preclinical development (studies in monkeys are ongoing), targeting the adhesion molecule CD99. This surface antigen is overexpressed in Ewing's sarcoma (EWS), in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS). This mAb has been shown to be effective in inducing cell death in EWS, ALL and AML cells, especially in leukemic stem cells.

Anti-CEACAM1: The other DIATHEVA program in oncology include an antibody targeting CEACAM1 antigen that is expressed in a large array of tumors especially at more advanced stage and have a role in the immunoregulation and immune-evasion. In particular, CEACAM1 is emerging as a novel immune checkpoint target involved in the inhibition of antitumor immune responses. In addition, CEACAM1 regulates TIM-3-mediate tolerance and exhaustion of T lymphocytes. We have demonstrated that this antibody is able to enhance NK cell- mediated cytotoxicity of malignant melanoma cells by blocking the CEACAM1 homophilic interactions.

Anti-1,3 beta glucans: The lead candidate in the field of fungal infection treatment is a new humanized IgG1 monoclonal antibody called DIA-51. It binds selectively 1,3-beta glucans, fundamental components of the fungal cell wall of pathogenic fungi. This mAb is effective in vitro and in vivo in murine models of candida and aspergillus infections and is effective in vitro against the multidrug resistant Candida auris.

ASSET DEVELOPMENT STAGE

Anti-CD99: late preclinical (IND enabling studies)

Anti-CEACAM1: preclinical

Anti-beta 1,3 glucans: preclinical

DORIAN THERAPEUTICS

AREA OF ACTIVITY
Biotech

FOUNDED
2018

HEADQUARTERS
733 Industrial Road,
San Carlos, CA

www.doriantherapeutics.com

MEETING'S GOAL

Fundraising - networking

CLINICAL INDICATION / TARGET MARKET

Age related diseases (1st indication: osteoarthritis) - cell therapy (CAR-T)

ASSET DESCRIPTION

We are developing small molecules and genetic tools to modulate aging at the cellular level by activating proprietary pathways identified in stem cells.

ASSET DEVELOPMENT STAGE

Preclinical

ENDOTICS

AREA OF ACTIVITY
Medical devices

FOUNDED
2014

HEADQUARTERS
Via cava 26, Cascina (PI), Italy

www.endotics.com

MEETING'S GOAL

Fundraising and M&A

CLINICAL INDICATION / TARGET MARKET

Colon cancer / colonoscopy in general and screening of colon cancer

ASSET DESCRIPTION

Soft Robotics Self Propelling Disposable Technology allowing a painless, safer, easier colonoscopy.

ASSET DEVELOPMENT STAGE

CE, ISO, TGA, FDA approved.

EUROMED PHARMA US

AREA OF ACTIVITY
Pharmaceutics

FOUNDED
-

HEADQUARTERS
548 West 28th Street, Ste 336
New York, NY 10001, USA

www.euromed-pharma.com

MEETING'S GOAL

Customer Acquisition

CLINICAL INDICATION / TARGET MARKET

Pharma & Biotech

ASSET DESCRIPTION

We deliver strategic services tailored to support companies in their quest to better healthcare. We support each industry player from drug development through the post-marketing phases. We offer solutions in CTS services, Clinical GMP Packaging, Labeling and Distribution, IMP management, Early Access and Named Patient Programs, Pharma Order to cash solutions, and Supply Chain & Logistics. Being one of the Petrone Group companies, Euromed Pharma is positioned at the forefront of innovation in pharmaceutical distribution.

ASSET DEVELOPMENT STAGE

All Phases

GENETA SCIENCE

AREA OF ACTIVITY
Biotech

FOUNDED
2014

HEADQUARTERS
Milano - New York

www.genenta.com

MEETING'S GOAL

Fundraising

CLINICAL INDICATION / TARGET MARKET

Immuno-oncology - Gene & Cell Therapy

ASSET DESCRIPTION

We develop a gene transfer strategy into hematopoietic cells to target specific anti-tumor proteins. A definite vector delivers the gene into the cells. We use a combination of transcriptional and mediated control gene expression to selectively direct the anti-tumor proteins to the tumor area. Based on our exclusive mechanism, the immune system cells are reactivated and armed with a potent drug.

ASSET DEVELOPMENT STAGE

Phase 1/2

HOLOSTEM TERAPIE AVANZATE

AREA OF ACTIVITY
Biotech

FOUNDED
2008

HEADQUARTERS
Via Glauco Gottardi 100, 41125
Modena, Italy

www.holostem.com

MEETING'S GOAL

Fundraising & Venture interaction

CLINICAL INDICATION / TARGET MARKET

Regenerative Medicine for rare epithelial diseases

ASSET DESCRIPTION

Holostem is developing epithelial stem cells-mediated Advanced Therapy Medicinal Products (ATMPs) for cell therapy and gene therapy at different stage of development.

ASSET DEVELOPMENT STAGE

The fist stem cell ATMP approved in Europe (Holoclar, used for moderate to severe Limbal Stem Cell Deficiency);

4 ATMPs in Phase 1/2 indicated, respectively, for complete bilateral Limbal Stem Cell Deficiency, Posterior Hypospadias, Recessive Dystrophic Epidermolysis Bullosa, COL17-dependent Junctional Epidermolysis Bullosa

1 ATMP starting Phase 3 indicated for LAMB3-dependent Junctional Epidermolysis Bullosa

IFOM, THE FIRC INSTITUTE OF MOLECULAR ONCOLOGY

AREA OF ACTIVITY
Biotech

FOUNDED
1998

HEADQUARTERS
Via Adamello, 16 - 20139 Milano - Italy

www.ifom.eu

MEETING'S GOAL

Fundraising to allow selection of a clinical candidate in Q1 2022 and start clinical studies in respiratory indications within mid-2023.

CLINICAL INDICATION / TARGET MARKET

Degenerative and age-dependent diseases associated with telomere dysfunction. First indication selected: Familial and sporadic Idiopathic Pulmonary Fibrosis, 50.000 patients with short telomeres.

ASSET DESCRIPTION

Antisense oligonucleotides (tASO) that inhibit the DNA damage response selectively at telomeres and delay cellular senescence and aging.

ASSET DEVELOPMENT STAGE

Preclinical

IKINOVA

AREA OF ACTIVITY
eHealth, mHealth, telemedicine

FOUNDED
2020

HEADQUARTERS
Via Alessandria 2, Acqui Terme (AL), Italy

www.ikinova.com

MEETING'S GOAL

Fundraising

CLINICAL INDICATION / TARGET MARKET

Relationship between Hospital and virtual surgery

ASSET DESCRIPTION

Monitoring platform with medical device and interactive tools.

ASSET DEVELOPMENT STAGE

Hospital pilot

IS CLEAN AIR ITALIA

AREA OF ACTIVITY
Medical Devices

FOUNDED
02/05/15

HEADQUARTERS
Albano Laziale RM, Italy
London (UK),
Hong Kong

www.iscleanair.com

MEETING'S GOAL

Following the Series A fund raising (1.2m euros) in 2017, our goal is to achieve and secure a Series B fund raising of at least 10m euros by 2021. This will include both the Air Purification and Virus detection and disinfection capabilities and knowhow. Since 2019 we are actively looking for and signing agreements with large corporations in Europe and Internationally to license our technology, with currently 5 already signed and another 3 close to being signed. In terms of Mergers and Acquisitions (M&A), we are continuously scouting for complementary technologies to support and add value to APA technology, and the Series B fund request includes a percentage dedicated specifically to M&A.

CLINICAL INDICATION / TARGET MARKET

ICA Air Pollution Abatement (APA) Technology has been certified as medical device CLASS 1 because it is able to remove nano-particles carrying viruses in the air. Our technology embeds UV-C and photocatalyst systems to fully kill viruses and bacteria trapped within the water tank of the APA purification devices. Because APA is the only one in the world using simple water, we have the ability to clinically test our water through samples to verify the presence of the virus in indoor spaces using cheap and fast standard RNA lab tests. This process can be extended to bacteria as well. Our target market, in addition to Air Purification, is the sanitization and decontamination of sensitive indoor environments from viruses and bacteria, as well as reducing their density in the air and minimizing the viral spread and risk of infection. This new market, which is very recent, has been estimated to value over £100b by 2023, and includes urban and industrial sites such as schools, care homes, universities, theatres, shopping centres and offices/production plants where large groups of individuals or vulnerable people are present.

ASSET DESCRIPTION

ICA ICA owns a production plant in Rome which enables us to produce up to 1500 units per year, in addition to our established local and international partnerships which allow us to quickly increase our production at both the EU and International level, so we can quickly scale up production to accommodate growing demand. Another key asset is represented by our team (21 @work) of dynamic and globally distributed professionals, with main offices in Rome, London and Hong Kong. Finally, we have agreements in place with several clinical labs (in Italy, UK, and Asia) for viral and bacterial testing

ASSET DEVELOPMENT STAGE

We are conducting Preclinical trials to assess the viral and bacterial residual to enable our Medical Device certification to be recognized at higher level (Class 2 and 3).

KITHER BIOTECH

AREA OF ACTIVITY
Biotech

FOUNDED
2011

HEADQUARTERS
Via Nizza 52, 10126 Torino, Italy

www.kitherbiotech.com

MEETING'S GOAL

In 2019, the company raised a Series A round of $6.5mln. It has now launched a new round of up to $10mln to complete a Phase 1/2A clinical trial in Cystic Fibrosis, and to complete the pre-clinical phase of the IPF programme.

Kither biotech has already received soft commitments for about $3mln from existing and new European investors. The company is keen to partner with a US-based biotech investor that can provide strategic support in pushing product development and in leading the expansion in the key US market.

CLINICAL INDICATION / TARGET MARKET

Kither Biotech is a pre-clinical stage company developing new therapies for rare pulmonary diseases with high unmet needs. The company leverages its unique expertise in delivery of signal transduction inhibition to the respiratory system, leading to strongly improved delivery to the lung.

ASSET DESCRIPTION

The key product is a proprietary compound to treat Cystic Fibrosis with pre-clinical data showing strong superiority vs. the current market leader, with the potential to radically change the treatment paradigm of Cystic Fibrosis, a global market projected to grow in excess of $20 billion.

The pipeline also includes a proprietary a small molecule that has shown strong results in pre-clinical models for Idiopathic Pulmonary Fibrosis (IPF), a lethal orphan disease, and has potential long-term use with COVID-19 patients.

ASSET DEVELOPMENT STAGE

The Cystic Fibrosis program is in pre-clinical phase and a Phase 1/2a clinical trial (with efficacy studies on some CF patients) is due to start by Q4 2021. The company is working on the design of the clinical trial with the support of world-renowned clinical KOL experts in CF and other respiratory diseases.

LABORATORIO FARMACEUTICO

AREA OF ACTIVITY
Biotech

FOUNDED
1946

HEADQUARTERS
Via Dante Alighieri, 71 - 18038
Sanremo - Italy

www.labct.it

MEETING'S GOAL

Fundraising, Out-licensing

CLINICAL INDICATION / TARGET MARKET

Treatment of alcohol use disorders.

ASSET DESCRIPTION

A new molecular entity, worldwide patented, with pre-clinical and clinical phase 1 completed (in UK). IND granted by FDA, with the first phase 1b/2a study completed in patients and a second phase 2a study (imaging study) performed in US.

ASSET DEVELOPMENT STAGE

A large phase 2b study to confirm efficacy and safety in alcoholic patients and other ancillary studies to lead the new compound to the confirmatory clinical phase 3.

MENARINI SILICON BIOSYSTEMS

AREA OF ACTIVITY
Diagnostics Equipment
and accessories

FOUNDED
2011

HEADQUARTERS
Via Giuseppe di Vittorio, 21 b/3
40013 Castel Maggiore (BO), Italy

www.siliconbiosystems.com

MEETING'S GOAL

Strategic Alliance

CLINICAL INDICATION / TARGET MARKET

Oncology - Liquid Biopsy

ASSET DESCRIPTION

Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley, PA, US, it is a wholly owned subsidiary of the Menarini Group.

Leader in the cell based liquid biopsy market, the Company offers unique rare cell technologies and solutions that provide clinical researchers with access to unparalleled resolution in the study of cells and their molecular characterization starting from a blood sample.

The company's CELLSEARCH and DEPArray NxT technologies together provide an end-to-end solution for enumeration, sorting and characterization of rare cells with single-cell precision.

ASSET DEVELOPMENT STAGE

Clinical Validity/Analytical Validity/Feasibility

MULTIPLY LABS

AREA OF ACTIVITY
Robotics, Pharma

FOUNDED
2016

HEADQUARTERS
1760 Cesar Chavez ste d,
San Francisco, CA 94124

www.multiplylabs.com

MEETING'S GOAL

Fundraising, Partnerships.

CLINICAL INDICATION / TARGET MARKET

Our robots manufacture individualized drugs for both the clinical trial and advanced biologics markets.

ASSET DESCRIPTION

Multiply Labs develops robotic systems that manufacture individualized drugs rapidly and efficiently - allowing these life-saving medicines to achieve industrial scale. Multiply Labs' automated systems consist of a robotic arm that shuttles the drug products through the manufacturing process. Each task in the process is executed by an automated module, based on state-of-the art equipment. The whole process is controlled from the cloud, and the system automatically created a digital record for each drug product.

See a video of the system in action here:

https://www.youtube.com/watch?v=S-bhQi2JO8E.

ASSET DEVELOPMENT STAGE

Multiply Labs' robots are being deployed for the manufacturing of clinical trial material.

MYSURABLE

AREA OF ACTIVITY
Medical devices

FOUNDED
2018

HEADQUARTERS
Viale G. Fanin 48 40127
Bologna, Italy

www.mysurable.it

MEETING'S GOAL

Fundraising

CLINICAL INDICATION / TARGET MARKET

Mysurable's mioTest® in the first instance aims to evaluate muscular performance and detect sarcopenia, the excessive loss of muscle mass age-related, one of the major causes of frailty and disability in the elderly. In its development it becomes a medical therapy system. mioTest® targets diagnostic medical devices market and later specific therapy market.

ASSET DESCRIPTION

MioTest@ is an innovative cloud-based system that includes all tests (e.g. SARC F) and devices (e.g. bioimpedance meter) necessary to identify sarcopenia, interprets the test results, and provides personalised suggestions for treatment (combination of diet, physical activity protocols and food integrations). Moreover, our solution optimizes therapy over time and adapts it to common chronic diseases of aging (COPD, heart failure, diabetes, etc.)

ASSET DEVELOPMENT STAGE

MioTest® product's range is at different levels of development: from TRL7 for base version, already operative in pilot centers, to TRL3 and 4 for more advanced versions.

PROMETHEUS

AREA OF ACTIVITY
Medical Devices

FOUNDED
2017

HEADQUARTERS
Via Trento, 30, Parma (PR),
Italy

www.prometheus3d.com

MEETING'S GOAL

Fundraising

CLINICAL INDICATION / TARGET MARKET

Medical Device for the treatment of Chronic wounds

ASSET DESCRIPTION

Ematik: a bioabsorbable patch for wounds, combining patient's own blood with a biopolymeric mixture. The patch acts like a second skin: reducing healing times by 50% without scars.

ASSET DESCRIPTION STAGE

The product is now in the veterinary market (since Feb. 2020) for animal wound care. In the human market it is classified as a Medical Device of class III, with the following phase: preclinical testing + human clinical trial phase.

REITHERA

AREA OF ACTIVITY
Vaccines

FOUNDED
2013

HEADQUARTERS
Via di Castel Romano, 10128 – Rome, Italy

www.reithera.com

MEETING'S GOAL

Reithera is seeking potential partners able to support the development and registration of GRAd-COV2 vaccine. With this goal, we are opening to beginning discussions with VCs and/or licensors for the product in specific countries

CLINICAL INDICATION / TARGET MARKET

Prevention of Covid-19 infection in subjects aged > 18 years old

ASSET DESCRIPTION

ReiThera is a fast growing biopharmaceutical company dedicated to the technology development, GMP manufacturing and clinical translation of vector gene-delivery platforms by exploiting viral vectors platforms (Adv, MVA, AAV) to be used as genetic vaccines and gene therapy for the treatment of life threatening diseases. ReiThera is developing GRAd-COV2, a vaccine against Covid-19, which consists in a new scimian adeno vector delivering the Covid Spike protein and able to induce an immune response.

ASSET DEVELOPMENT STAGE

GRAd-COV2 vaccine preclinical studies in animal models (rodents and rhesus macaques) supported successfully the vaccine candidate in terms of safety and immunogenicity.

A phase I clinical trial is ongoing and the preliminary results have shown the vaccine is well tolerated and Immunogenic.

A phase II/III clinical trial will be activated soon.

SERVERNET

AREA OF ACTIVITY
eHealth, mHealth, telemedicine

FOUNDED
2013

HEADQUARTERS
Località Padriciano, 99 - Area Science Park, Italy

www.servernet.it

MEETING'S GOAL

Fundraising and M&A

CLINICAL INDICATION / TARGET MARKET

Artificial Intelligence infrastructure platform and Medical Data Governance in IM-IoT (Industrial and Medical Internet of Things) Technologies for Hospital efficiency improvement.

ASSET DESCRIPTION

IM-IoT Medical Grade Hardware, Medical Data Governance Platform as a Service (PaaS).

ASSET DEVELOPMENT STAGE

Marketed Medical Hardware, Deployed Covid Monitoring Solution (live patients), Medical Data Governance on going PoC, Market ready Multivendor Remote Monitoring Medical Devices PaaS.

SIFI

AREA OF ACTIVITY
Pharmaceutics

FOUNDED
1935

HEADQUARTERS
Via Ercole Patti, 36 - Aci S. Antonio (CT), Italy

www.sifigroup.com

MEETING'S GOAL

Out-licensing

CLINICAL INDICATION / TARGET MARKET

Ophthalmology/Degenerative pathologies of the retina/Age-related macular degeneration/Diabetic retinopathy.

ASSET DESCRIPTION

SIFI S.p.A. has developed a novel proprietary Nanostructured Microemulsions System (NaMESys) to be used as a pharmaceutically acceptable carrier of small-molecule drugs useful for treating diseases of the eye, particularly those affecting the retina. NaMESys contains surfactants and co-surfactants mixed in specific ratios and amounts that give this system its unique properties including i) high chemical and physical stability, ii) improved bioavailability and efficacy, and iii) enhanced biocompatibility. NaMESys is currently protected by a US patent, and additional protection will be sought through a PCT procedure already in place. NaMESys is designed for a wide range of ocular diseases but, most importantly, following topical administration to the surface of the eye, this system has proved to effectively deliver therapeutically relevant amounts of drugs in models of retinal degenerative pathologies, including age-related macular degeneration and diabetic retinopathy.

ASSET DEVELOPMENT STAGE

Preclinical

TRANSACTIVA

AREA OF ACTIVITY
Biotech

FOUNDED
2001

HEADQUARTERS
c/o Friuli Innovazione, via Jacopo Linussio 51, 33100 Udine (UD), Italy

www.transactiva.it

MEETING'S GOAL

Primary goal - Fundraising: 2M€ to complete the preclinical phase.
Secondary goal - Out-licensing to Pharma.

CLINICAL INDICATION / TARGET MARKET

Clinical indication: Target rare skin disorders involving mucocutaneous ulcerations.

ASSET DESCRIPTION

New topical treatment for rare skin disorders based on a new biologic drug (anti-TNFalpha monoclonal antibody) produced in an innovative green platform.

ASSET DEVELOPMENT STAGE

Preclinical phase

U-CARE MEDICAL

AREA OF ACTIVITY
IT Application for Health

FOUNDED
-

HEADQUARTERS
Via Pier Carlo Boggio, 59
1022 Torino, Italy

www.u-caremedical.com

MEETING'S GOAL

Fundraising and Networking.

CLINICAL INDICATION / TARGET MARKET

Intensive Unit Care & Nephrology department

ASSET DESCRIPTION

We have a PCT Patent to protect our technology solution.

ASSET DEVELOPMENT STAGE

We are in preclinical phase. We are testing our hardware (Technical features) at San Giovanni Bosco (TO)

VAXXIT

AREA OF ACTIVITY
Vaccines

FOUNDED
2017

HEADQUARTERS
Via dei Valeri 1, Roma, Italy

www.vaxxit.com

MEETING'S GOAL

VAXXIT aims at bringing R-TAT to market and at generating pivotal human efficacy data for HSV TAT. Vaxxit aims to raise €20-25 million from equity/corporate partners and € 10-15 million in soft funding from European agencies to conduct phase III studies and register R-TAT in Europe and South Africa. The HSV TAT program will be funded with grants, R&D partnerships or through a Vaxxit's spin-off company open to investors and commercial partners with interest in HSV vaccines. Ready to discuss all options that may become available to achieve either or both goals.

CLINICAL INDICATION / TARGET MARKET

A phase III-ready therapeutic vaccine for HIV+ people unresponsive to chronic pharmacological treatment, about 20 million or 50% of the total 40 million world HIV population. Also developing a promising pre-clinical vaccine against Herpes for the 500 million global infections.

ASSET DESCRIPTION

VAXXIT 's lead product is R-TAT, a potent immunotherapy for HIV+ people on chronic drug therapy that has shown robust immune reconstitution and drastic reduction of latent HIV reservoirs in 8-year phase 2 studies in Italy and South Africa. HSV TAT, a Tat-expressing HSV vaccine, has shown 100% efficacy against a lethal HSV infection in mice studies; testing in guinea pigs towards an IND for phase 1 studies are planned with a $500K R&D grant. Vaxxit's R&D partners are scientists at the Italian National AIDS Center and the University of Ferrara.

ASSET TYPE

R-TAT is ready for phase 3 studies in South Africa, where the clinical research infrastructure is in a high state of readiness following favorable pre-IND meetings with regulatory agencies.

HSV TAT is completing pre-clinical animal testing with a €400K grant moving towards phase I/II safety, immunogenicity and efficacy studies."

ITA
ITALIAN TRADE AGENCY

LOS ANGELES
1900 Avenue of the Stars
Suite 350
Los Angeles, CA 90067
T. +1 323 879 0950
F. +1 310 203 8335
losangeles@ice.it

CHICAGO
401 N. Michigan Avenue
Suite 1720
Chicago, IL 60611
T. +1 312 670 4360
F. +1 312 670 5147
chicago@ice.it

HOUSTON
777 Post Oak Blvd
Suite 320
Houston, TX 77056
T. +1 281 888 4288
F. +1 281 974 3100
houston@ice.it

MIAMI
1 SE 3rd Avenue
Suite 1000
Miami, FL 33131
T. +1 305 461 3896
F. +1 786 497 8900
miami@ice.it

NEW YORK
33 East 67th Street
New York, NY 10065
T. +1 212 980 1500
F. +1 212 758 1050
newyork@ice.it

ROME
Via Liszt, 21
00144 Rome, Italy
T. +39 06 59921
F. +39 06 89280353
fdi@ice.it

ITA www.ice.it